Why Nigeria Is Building Its Healthcare Economy: Tinubu Explains Push for Local Medicine Production and Medical Equipment!

Reported by Weng Patrick Atokor l Journalist at Weng Global

Nigeria is intensifying efforts to develop its domestic healthcare industry by expanding local pharmaceutical manufacturing, attracting private investment and strengthening the production of medical equipment and essential health products.

President Bola Ahmed Tinubu says the country must reduce its dependence on imported medicines and medical supplies while creating an industrial ecosystem capable of supporting healthcare delivery, generating employment and contributing to economic growth.

In an article published on November 15, 2026, titled Why We Are Building Nigeria’s Healthcare Economy, Tinubu explained that the government’s strategy is designed to ensure that more of the money Nigerians spend on healthcare supports businesses, workers and manufacturing activities within the country.

The President argued that Nigeria has the population, professional expertise and existing pharmaceutical industry needed to become a stronger healthcare manufacturing centre.

However, he acknowledged that dependence on imported health products and the movement of patients abroad for medical treatment continue to limit the country’s ability to retain healthcare-related economic opportunities.

The initiative represents a broader government strategy to connect healthcare development with industrialisation, investment, technology transfer and job creation.

For Nigeria, the ambition is not simply to manufacture more medicines. It is to build an economy in which pharmaceutical companies, medical equipment producers, diagnostic manufacturers, hospitals, research institutions and healthcare technology businesses can operate within a stronger domestic value chain.

What Is Nigeria’s Healthcare Economy?

The healthcare economy refers to the industries, businesses, services and economic activities connected to the provision of healthcare.

It includes hospitals, pharmaceutical manufacturing, medical equipment production, laboratory services, diagnostic technologies, health insurance, medical research, logistics and healthcare technology.

Traditionally, discussions about healthcare development in Nigeria have focused heavily on hospitals, doctors, nurses, medicines and access to medical treatment.

However, every healthcare system also depends on a wider network of industries responsible for producing and supplying the products and services used by medical professionals.

For example, a hospital requires medicines, diagnostic equipment, surgical instruments, laboratory materials, medical oxygen and other essential supplies to operate effectively.

When these products are imported, a significant portion of the money spent on healthcare leaves the domestic economy.

But when they are manufactured locally, the economic benefits can extend to Nigerian pharmaceutical companies, engineers, scientists, technicians, suppliers, transport operators and other businesses.

This is the economic opportunity the Federal Government wants to develop.

Through local production, Nigeria hopes to retain more healthcare expenditure within its economy while creating businesses capable of serving both domestic and international markets.

Why Nigeria Wants to Reduce Dependence on Imported Medicines

One of the major reasons behind the government’s strategy is Nigeria’s historical dependence on imported pharmaceutical products.

The National Agency for Food and Drug Administration and Control (NAFDAC) has previously estimated that Nigeria depended on imports for approximately 70 per cent of its medicines.

This dependence creates economic and healthcare challenges.

First, pharmaceutical imports require foreign exchange. When the naira depreciates against international currencies, the cost of purchasing imported medicines and production materials can increase.

These additional costs can affect pharmaceutical companies, hospitals, pharmacies and ultimately patients.

Second, dependence on international suppliers exposes Nigeria to disruptions beyond its control.

Global conflicts, shipping difficulties, pandemics, trade restrictions and production shortages can affect the availability of essential medical products.

The COVID-19 pandemic demonstrated how international supply-chain disruptions can affect countries that rely heavily on foreign manufacturers.

Third, excessive dependence on imports limits opportunities for domestic industrial development.

When pharmaceutical manufacturing takes place outside Nigeria, the country loses opportunities to develop production expertise, create specialised employment and strengthen its industrial base.

According to NAFDAC’s May 2026 report on the pharmaceutical industry’s development, its 5+5 Policy has contributed to increased domestic production, with more than 70 per cent of the products covered by the policy reportedly being manufactured locally.

However, this figure relates specifically to products covered by the policy and should not be interpreted as meaning that Nigeria produces more than 70 per cent of all medicines consumed nationally. NAFDAC

The government’s broader ambition is to expand local production across more categories of essential healthcare products.

The Presidential Initiative Driving the Transformation

The central programme behind the government’s healthcare industrialisation strategy is the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC).

Established by President Tinubu in October 2023, PVAC was designed to attract investment into Nigeria’s healthcare sector and strengthen the country’s capacity to manufacture health products and deliver specialised medical services.

The initiative operates around three major objectives.

Expanding domestic manufacturing: Increasing Nigerian production of pharmaceuticals, vaccines, medical devices, diagnostic products and other essential healthcare supplies.

Improving healthcare services: Strengthening the quality of medical services available within Nigeria and reducing the need for Nigerians to travel abroad for treatment.

Creating quality employment: Developing jobs across pharmaceutical production, medical technology, healthcare delivery, research, distribution and other related industries.

PVAC also seeks to coordinate government agencies, regulators, manufacturers, investors and development partners.

This coordination is important because developing a manufacturing industry requires several institutions to work together.

For example, pharmaceutical companies need access to financing, regulatory approvals, production equipment, raw materials, electricity and reliable markets.

Without these supporting conditions, even companies with substantial investment may struggle to operate competitively.

The government therefore wants to create an environment in which investment in healthcare manufacturing becomes commercially sustainable. PVAC

Government Introduces Incentives to Support Local Production

One of the major interventions supporting the strategy is the Executive Order on Increasing Local Production of Healthcare Products.

Published in October 2024, the Executive Order introduced fiscal and non-fiscal incentives intended to reduce the cost of manufacturing medicines and other healthcare products in Nigeria.

Its provisions include:

  • Tariff and excise-duty exemptions for specified pharmaceutical machinery and equipment.
  • Tax relief on eligible active pharmaceutical ingredients and other manufacturing materials.
  • Incentives for local pharmaceutical and medical-device production.
  • Framework contracts and volume guarantees to support domestic manufacturers.
  • Improved coordination and regulatory approval processes.

The purpose is to reduce some of the financial barriers facing manufacturers and encourage businesses to invest in domestic production.

In his November 15 article, Tinubu disclosed that the government approved more than ₦24 billion in waivers for 75 pharmaceutical manufacturers between January 2025 and June 2026.

The incentives are intended to make local production more competitive and encourage manufacturers to expand their operations.

However, the government will need to ensure that these financial incentives translate into measurable improvements in production capacity, medicine availability and affordability. Nigerian NewsDirect +1

Ten Manufacturing Facilities Commissioned Under the Programme

Nigeria’s healthcare industrialisation strategy is beginning to produce reported manufacturing developments.

At the Third Nigeria Health Sector Joint Annual Review held in Abuja in November 2026, Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, disclosed that ten factories or manufacturing lines had been commissioned under the government’s healthcare manufacturing programme.

Six of the facilities were commissioned in 2026.

The manufacturing activities cover several important areas, including:

  • Pharmaceutical products.
  • Rapid diagnostic tests.
  • Long-lasting insecticide-treated mosquito nets.
  • Medical oxygen.

The development is significant because it extends beyond conventional medicine production to other essential products required by hospitals and public health programmes.

The Federal Government also reported 12 technology-transfer agreements and a prospective investment pipeline exceeding $5 billion.

These agreements are intended to strengthen local manufacturing capacity by connecting Nigerian businesses with international technical expertise, production processes and manufacturing technologies.

However, the proposed investment pipeline should not be confused with money already invested. Converting these commitments into operational businesses remains an important part of the government’s responsibility.

The government has also identified the expansion of pharmaceutical manufacturing as a priority for the next phase of its healthcare reforms. fmino.gov.ng +1

How Technology Transfer Could Strengthen Nigeria’s Pharmaceutical Industry

An important component of Nigeria’s healthcare strategy is technology transfer.

Technology transfer occurs when companies, research institutions or international partners share technical knowledge, production methods, equipment expertise and manufacturing processes with domestic businesses.

For Nigeria, this could help local pharmaceutical companies move beyond producing basic medicines towards developing more advanced medical products.

International partnerships can also help Nigerian manufacturers improve production efficiency and meet internationally recognised quality standards.

For example, the government has highlighted partnerships involving the production of rapid diagnostic tests and other healthcare products.

Such arrangements could help Nigerian businesses develop the technical capacity required to manufacture products that previously depended heavily on international suppliers.

The long-term objective is to ensure that foreign investment does not simply establish production facilities in Nigeria but also strengthens domestic expertise.

This is important because a sustainable manufacturing industry requires skilled Nigerian workers, research capacity and the ability to maintain production technologies over time.

Why Local Manufacturing Could Create More Jobs

Building a healthcare economy could create employment opportunities across several industries.

Pharmaceutical manufacturing requires pharmacists, chemists, engineers, laboratory technicians, production workers and quality-control specialists.

Medical equipment manufacturing also requires technical professionals, industrial designers, software developers, engineers and skilled production personnel.

Beyond direct manufacturing employment, supporting businesses could benefit from increased industrial activity.

These include:

  • Packaging and printing companies.
  • Transportation and logistics businesses.
  • Chemical and raw-material suppliers.
  • Equipment maintenance companies.
  • Warehousing and distribution businesses.
  • Technology and software companies.
  • Research and development institutions.

This means the expansion of healthcare manufacturing could create opportunities for both established businesses and small enterprises.

For young Nigerians, the sector could provide employment pathways beyond traditional medical professions.

A person does not necessarily need to become a doctor or nurse to participate in the healthcare economy. Pharmaceutical engineering, medical technology, laboratory science, data management, manufacturing and logistics are also important parts of the industry.

The government wants healthcare investment to support a wider network of productive businesses and skilled employment.

Nigeria Also Wants to Reduce Medical Tourism

Another important part of the government’s strategy is improving the quality of healthcare services available within Nigeria.

Medical tourism occurs when individuals travel outside their country to obtain medical treatment.

Some Nigerians travel abroad for specialised procedures, cancer treatment, advanced diagnostics and other medical services.

This creates additional expenses for patients and families, including transportation, accommodation, medical bills and other costs associated with receiving treatment abroad.

It also means that money spent on those services supports healthcare facilities and professionals in other countries.

Tinubu argues that Nigeria needs to develop stronger domestic healthcare services so that more patients can receive quality treatment at home.

This will require investment in hospitals, specialist centres, diagnostic facilities, modern equipment, medical research and professional training.

The objective is not simply to discourage Nigerians from travelling abroad but to improve the quality, availability and affordability of treatment within the country.

If successful, the strategy could strengthen confidence in Nigeria’s healthcare system while retaining more healthcare-related expenditure within the economy.

However, developing specialised healthcare services will require sustained investment and improvements in medical infrastructure, staffing and patient care.

The Importance of Government Procurement

Local manufacturers need reliable customers to sustain their businesses.

Even when a company has the equipment and technical capacity to manufacture medicines, it may struggle if it cannot secure sufficient demand for its products.

This makes government procurement an important part of Nigeria’s healthcare industrialisation strategy.

Government hospitals, public health programmes and other healthcare institutions purchase significant quantities of medicines and medical supplies.

By improving procurement arrangements and supporting qualified local manufacturers, the government hopes to create a more predictable market for domestic production.

Nigeria’s Health Products Supply System Policy provides a framework for prioritising locally manufactured healthcare products while maintaining requirements for quality, affordability and value for money.

The policy also supports pooled procurement, through which purchasing requirements can be consolidated to improve negotiating power and reduce costs.

One of the initiatives highlighted by the government is Medipool, a group purchasing organisation designed to consolidate demand for medicines and other healthcare commodities.

The approach is intended to help manufacturers plan production while enabling healthcare institutions to obtain products more efficiently.

Nevertheless, procurement decisions must remain transparent and competitive. Local manufacturers must demonstrate that their products meet the required quality standards and provide value for money.

Supporting domestic industry should not come at the expense of patients’ safety or access to affordable medicines. Health.gov.ng +1

Challenges Nigeria Must Address

Despite the opportunities, building a competitive healthcare economy will require the government to address several structural challenges.

1. Unreliable electricity

Pharmaceutical manufacturing requires dependable electricity to operate machinery, maintain production conditions and preserve sensitive medical products.

Frequent power interruptions can increase operating costs and reduce manufacturing efficiency.

2. High production costs

Local manufacturers face expenses involving machinery, raw materials, transportation, labour and infrastructure.

Unless these costs are reduced, Nigerian businesses may struggle to compete with international manufacturers.

3. Dependence on imported raw materials

Manufacturing medicines locally does not automatically eliminate import dependence.

Many pharmaceutical companies still rely on imported active pharmaceutical ingredients and specialised chemicals.

Developing domestic capacity to produce these materials will be important for achieving deeper industrial independence.

4. Access to financing

Pharmaceutical manufacturing requires significant capital investment.

Businesses need affordable financing to construct facilities, acquire equipment, employ skilled workers and expand production.

High borrowing costs could discourage investment, particularly among small and medium-sized manufacturers.

5. Quality assurance

Increasing domestic production must not weaken medicine safety standards.

NAFDAC must continue inspecting facilities, testing products and enforcing regulations against substandard and falsified medicines.

The agency reported in November 2026 that it had conducted 5,532 enforcement activities during the period under review, alongside seizures and the closure of facilities involved in regulatory violations.

Maintaining strong regulatory oversight will be essential to building public confidence in Nigerian-made medicines. fmino.gov.ng

What Does This Mean for Africa?

Nigeria’s healthcare manufacturing ambitions could have implications beyond its domestic market.

With its large population and established pharmaceutical industry, the country has the potential to become an important supplier of healthcare products across Africa.

The African Continental Free Trade Area (AfCFTA) provides an opportunity for Nigerian manufacturers to explore wider regional markets.

If domestic companies can produce quality-assured medicines, diagnostic products and medical equipment at competitive prices, they could expand into other African countries.

This could encourage regional trade, industrial partnerships, technology exchange and investment.

It could also contribute to Africa’s broader effort to reduce dependence on pharmaceutical imports from outside the continent.

However, Nigeria must develop internationally competitive products, reliable distribution networks and strong regulatory systems before it can fully benefit from these opportunities.

The country must also ensure that its domestic healthcare needs are adequately served as export ambitions grow.

What Happens Next?

The next phase of Nigeria’s healthcare economy strategy will depend on whether announced policies, investments and partnerships translate into sustainable production.

The Federal Government will need to focus on expanding manufacturing capacity, improving access to financing, strengthening regulatory institutions and creating reliable markets for locally produced healthcare products.

The reported investment pipeline exceeding $5 billion will require close monitoring to establish how much progresses into actual manufacturing operations.

Technology-transfer agreements must also produce measurable improvements in domestic skills, production capabilities and product quality.

For ordinary Nigerians, the most important indicators will be whether medicines become more affordable, hospitals obtain essential supplies more consistently and patients gain better access to quality healthcare.

The government has identified 2027 as an important period for consolidating health-sector reforms, making implementation and accountability particularly important.

Conclusion: Nigeria’s Healthcare Industry Could Become a Major Economic Driver

Nigeria’s plan to build a healthcare economy represents an attempt to connect public health development with industrial growth.

The strategy recognises that healthcare is not only about hospitals and medical treatment. It is also about the businesses, technologies, manufacturing facilities and skilled workers required to support an effective health system.

Through the Presidential Initiative for Unlocking the Healthcare Value Chain, the government wants to attract investment, expand local pharmaceutical manufacturing, strengthen medical technology production and reduce dependence on imported healthcare products.

The potential benefits include employment creation, industrial development, improved medicine security, technology transfer and opportunities for Nigerian businesses to compete in African markets.

However, policy announcements and investment commitments alone will not deliver these outcomes.

Nigeria must address infrastructure weaknesses, production costs, financing constraints and regulatory challenges while ensuring that local manufacturers produce safe, effective and affordable products.

Ultimately, the success of the healthcare economy will be measured not by the number of investment announcements or factories commissioned but by the improvements Nigerians experience in their everyday lives.

If the strategy delivers on its objectives, healthcare spending could become a stronger source of domestic industrial development, economic opportunity and improved public health.

For Nigeria, building a healthcare economy is therefore both an industrial ambition and an investment in the country’s long-term economic and human development.

Weng Global – Stories beyond borders

Sources

Leave a Reply

Your email address will not be published. Required fields are marked *